What it's for (Indications)
- Nystatin is an antifungal antibiotic primarily indicated for the treatment of candidiasis (moniliasis) caused by susceptible strains of *Candida* species.
- This encompasses a range of superficial fungal infections, including but not limited to, oral candidiasis (often referred to as thrush) in infants and adults, intestinal candidiasis, and local infections of the skin and mucous membranes.
- Specifically, nystatin formulations are used for cutaneous candidiasis, vulvovaginal candidiasis, and diaper rash when complicated by *Candida* infection.
- It is crucial to note that nystatin is not indicated for the treatment of systemic mycotic infections due to its negligible absorption from the gastrointestinal tract and skin.
- Its therapeutic utility is strictly limited to localized candidal infections where direct contact with the fungus can be achieved, making it ineffective for disseminated fungal diseases.
- Accurate diagnosis of candidiasis is essential prior to initiation of therapy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of nystatin varies significantly based on the specific formulation (oral suspension, tablets, topical cream, ointment, powder, vaginal tablets), route of administration, and the site and severity of the candidal infection. For oral candidiasis (thrush), the typical adult dosage of nystatin oral suspension is 400,000 to 600,000 units four times daily, with instructions to swish the medication thoroughly in the mouth for as long as possible before swallowing, to ensure maximum contact with the infected oral and pharyngeal mucosa. Infants and children may receive 100,000 to 200,000 units four times daily, or as directed by a pediatrician. For intestinal candidiasis, oral tablets or capsules typically contain 500,000 to 1,000,000 units taken three times daily. Topical nystatin creams, ointments, or powders are applied liberally to the affected skin areas two to three times daily until complete healing. Vaginal candidiasis is treated with nystatin vaginal tablets or suppositories, typically one tablet (100,000 or 200,000 units) inserted high into the vagina once daily, usually at bedtime, for 14 consecutive days. It is imperative that the full prescribed course of therapy is completed, even if symptoms improve, to prevent recurrence and ensure eradication of the infection. Specific dosages and duration should always be determined by a healthcare professional based on individual patient assessment and clinical guidelines. |
Safety & Warnings
Common Side Effects
- Nystatin is generally well-tolerated due to its poor absorption from the skin and gastrointestinal tract, which results in minimal systemic exposure and consequently, a low incidence of systemic side effects.
- Common side effects associated with oral nystatin formulations include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort or pain.
- These effects are usually mild, transient, and infrequently necessitate discontinuation of therapy.
- For topical nystatin applications, local irritation, burning, itching, erythema, or rash may occur at the site of application.
- These local reactions are typically mild and resolve with continued use or discontinuation if severe.
- Vaginal nystatin formulations can cause local irritation, burning, itching, and redness in the vaginal area.
- Allergic reactions, including rash, urticaria, and angioedema, are rare but possible with any route of administration and would require immediate cessation of the drug and appropriate medical management.
- In very rare instances, Stevens-Johnson syndrome has been reported.
- Patients should be advised to report any severe, persistent, or unusual side effects to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: **Serious Warnings** Nystatin does not currently carry a specific FDA-mandated Black Box Warning. However, healthcare professionals and patients should be aware of several serious considerations to ensure its safe and effective use. Nystatin's therapeutic efficacy is limited exclusively to the treatment of candidiasis caused by susceptible *Candida* species. It is critically important to establish a definitive diagnosis of candidiasis through appropriate clinical and laboratory methods before initiating therapy. Misdiagnosis can lead to ineffective treatment, delayed management of the actual underlying condition, and potentially the inappropriate use of an antifungal agent. Nystatin is not effective against systemic fungal infections, and its use in such conditions is inappropriate and potentially harmful, as it lacks significant systemic absorption and will not reach the site of a deep-seated infection. While generally well-tolerated, severe hypersensitivity reactions, though rare, can occur. Patients experiencing symptoms such as a severe widespread rash, urticaria, facial swelling, swelling of the tongue or throat, or difficulty breathing must discontinue the medication immediately and seek urgent medical attention. Treatment should also be discontinued if severe local irritation, burning, or sensitization occurs or worsens during therapy, especially with topical or vaginal applications, to avoid prolonged discomfort or allergic reactions. Adherence to the prescribed full course of treatment is crucial to prevent recurrence.
- While nystatin is largely well-tolerated, several important warnings and precautions should be considered to ensure its safe and effective use.
- It is crucial to emphasize that nystatin is effective *only* against *Candida* species and has no activity against other fungi, bacteria, or viruses.
- Therefore, a definitive diagnosis of candidiasis should be established prior to initiating therapy, particularly if the infection is widespread, persistent, or atypical in presentation.
- Nystatin is explicitly not indicated for the treatment of systemic mycoses; its use in such conditions is inappropriate given its negligible systemic absorption.
- In cases of irritation or sensitization developing with topical or oral use, especially if symptoms worsen or do not improve, treatment with nystatin should be discontinued, and appropriate alternative therapeutic measures should be instituted by a healthcare professional.
- Patients should be advised to complete the full course of therapy as prescribed, even if symptoms improve, to minimize the risk of relapse or the development of resistance.
- There are no known significant drug interactions associated with nystatin due to its extremely poor systemic absorption.
- Use in pregnant or lactating individuals should be carefully considered; however, topical and oral nystatin are generally considered safe due to minimal systemic absorption, making risks to the fetus or infant low, although clinical data are limited.
How it Works (Mechanism of Action)
Nystatin is a polyene antifungal antibiotic derived from *Streptomyces noursei*. Its fungicidal and fungistatic activity is attributed to its direct binding to sterols, primarily ergosterol, which are essential components of the fungal cell membrane. Ergosterol plays a crucial role in maintaining the structural integrity and functional viability of fungal cells. Upon binding to ergosterol, nystatin molecules become incorporated into the fungal cell membrane, leading to the formation of pores and channels. These structural alterations disrupt the integrity and permeability of the fungal cell membrane, resulting in the leakage of vital intracellular components, such as potassium, amino acids, and other essential cellular constituents. This efflux of critical molecules ultimately leads to metabolic disruption, cellular dysfunction, and the death of the fungal cell. Nystatin exhibits selective toxicity because human cell membranes contain cholesterol instead of ergosterol, making them significantly less susceptible to its disruptive effects. This selective mechanism underpins its utility in treating superficial candidal infections with minimal systemic toxicity.